Commercial Syn Bags Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- ✓Strong return on equity (ROE 16.1%)
- ✓Attractively valued vs sector (P/E 29x vs industry 52.7x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| HAL Hindustan Aeronautics Limited | ₹4,568 | ₹3.0L Cr | 33 | 7.44 | 24 | 32 | 0 |
| BEL Bharat Electronics Limited | ₹407 | ₹3.0L Cr | 49.4 | 12.41 | 27.6 | 36.5 | 0 |
| ABB ABB India Limited | ₹7,530 | ₹1.6L Cr | 104 | 20.35 | 22.4 | 29.9 | 0.01 |
| TMCV Tata Motors Limited | ₹412 +0.59% | ₹1.5L Cr | 38.6 | 10.71 | 34 | 35.9 | 0.44 |
| CUMMINSIND Cummins India Limited | ₹5,590 | ₹1.5L Cr | 62.3 | 18.27 | 30.2 | 39.5 | 0 |
| BHEL Bharat Heavy Electricals Limited | ₹417 | ₹1.5L Cr | 60.4 | 5.55 | 6.23 | 9.14 | 0.45 |
| CGPOWER CG Power and Industrial Solutions Limited | ₹912 | ₹1.4L Cr | 118 | 18.02 | 20.5 | 26.7 | 0.02 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
COMSYN · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 58.79% | 58.79% | 58.79% | 58.79% | 58.79% | 58.79% |
| FII | — | 0.11% | — | — | — | — |
| Public | 41.22% | 41.10% | 41.21% | 41.22% | 41.22% | 41.21% |
Corporate Events
To consider and approve the financial results for the period ended March 31, 2026 and other business matters
Dividend - Re 0.40 Per Share
Annual General Meeting
Latest News
All news →JSW Steel completes merger of ARCL, MCL, JRDL
*JSW Steel completes merger of ARCL, MCL, JRDL* — JSW Steel announced the receipt of the final NCLT order for the amalgamation of Amalgamated Rural Commercial Limited (ARCL), Maheshwari Commercial Limited (MCL), and JRDBL with itself. The merger is expected to streamline operations and enhance corporate efficiency. No financial terms were disclosed. 📊 *STOCKS:* JSWSTEEL | 🏢 *SECTOR:* Corporate | #MEDIUMIMPACT #Merger
ZF Commercial Vehicle CFO resigns, stock slides
*ZF Commercial Vehicle CFO resigns, stock slides* — ZF Commercial Vehicle Solutions India shares declined sharply after CFO Anupam Saksena resigned with immediate effect. The company confirmed the resignation but did not disclose reasons. Leadership instability raises concerns ahead of upcoming earnings. 📊 *STOCKS:* $ZFCV | 🏢 *SECTOR:* Auto | #HIGHIMPACT #CFOresignation
Tata Motors acquires Iveco in $4.4B global deal
*Tata Motors acquires Iveco in $4.4B global deal* — Tata Motors has completed its **$4.4 billion** acquisition of Italy’s Iveco Group, marking a major expansion in the global commercial vehicle market. The deal enhances Tata’s scale and technology access in Europe and emerging markets. It positions the company as a stronger global player in the heavy-duty truck segment. 📊 *STOCKS:* TATAMOTORS | 🏢 *SECTOR:* Auto | #HIGHIMPACT #Acquisition
ONGC discovers major natural gas reserve in Andaman Basin
*ONGC discovers major natural gas reserve in Andaman Basin.* This find could boost India’s domestic hydrocarbon production and reduce import dependence. Initial estimates suggest reserves of **~200 million cubic feet per day**, with commercial production expected in **3–4 years**. The discovery marks a strategic leap for India’s energy security. 📊 *STOCKS:* ONGC | 🏢 *SECTOR:* Energy | #HIGHIMPACT #NaturalGas
Oil India confirms major offshore natural gas discovery in Andaman
*Oil India confirms major offshore natural gas discovery in Andaman.* The find could bolster India’s domestic energy production and reduce import dependence. Initial estimates suggest reserves of **over 500 billion cubic feet**, marking a strategic milestone. Commercial production is expected within **3–4 years**, pending approvals. 📊 *STOCKS:* OIL | 🏢 *SECTOR:* Energy | #HIGHIMPACT #NaturalGas
RBI introduces measures to boost dollar inflows as rupee weakens
*RBI introduces measures to boost dollar inflows as rupee weakens.* The central bank has rolled out steps to attract more foreign currency inflows amid sustained depreciation pressure on the rupee. Measures include easing norms for external commercial borrowings and boosting investment limits for foreign investors. These moves aim to increase forex reserves and stabilize the rupee, which has fallen to **₹83.2 per USD** recently. 📊 *STOCKS:* | 🏢 *SECTOR:* Macro | #HIGHIMPACT #RBI
RBI introduces measures to boost dollar inflows as rupee weakens
*RBI introduces measures to boost dollar inflows as rupee weakens.* The central bank has rolled out several measures to attract more foreign currency inflows amid persistent rupee depreciation against the **$1 = ₹83.50** level. These include easing rules for External Commercial Borrowings and promoting NRI deposits. The move aims to strengthen forex reserves, currently at **$620 billion**, and stabilize volatility ahead of upcoming F&O expiry. 📊 *STOCKS:* | 🏢 *SECTOR:* Macro | #HIGHIMPACT #RBI
RBI unveils measures to boost dollar inflows
*RBI unveils measures to boost dollar inflows* aims to strengthen India’s forex reserves and stabilize the rupee. The central bank introduced regulatory relaxations for external commercial borrowings and NRI deposits. Measures include **$10 billion** in potential inflows and eased investment norms. These steps may improve liquidity and support the rupee against volatile global flows. 📊 *STOCKS:* | 🏢 *SECTOR:* Macro | #HIGHIMPACT #RBI
RBI finalizes new banking asset and income norms
*RBI finalizes new norms for asset classification and income recognition.* Banks must follow stricter provisioning and reporting standards effective immediately. The move aims to improve transparency and early detection of stressed assets. Rules apply uniformly across all scheduled commercial banks. 📊 *STOCKS:* | 🏢 *SECTOR:* Banking | #HIGHIMPACT #RBI
Biocon announces pivotal clinical data for Yesafili biosimilar
*Biocon announces pivotal clinical data for Yesafili biosimilar*. Biocon has announced the publication of pivotal clinical data supporting the effectiveness of Yesafili, its biosimilar to Eylea® (Aflibercept), in a press release dated July 09, 2026. The data reinforces the drug’s potential in ophthalmic indications and could support future regulatory approvals and market expansion. Positive clinical outcomes may enhance commercial prospects in the growing biosimilars market. 📊 *STOCKS:* BIOCON | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹97.48 Cr ▼1.0% | ₹98.45 Cr ▲8.8% | ₹90.51 Cr ▼7.4% | ₹97.79 Cr ▲13.1% | ₹86.49 Cr ▼0.2% | ₹86.65 Cr ▲12.7% | ₹76.89 Cr ▲10.4% | ₹69.63 Cr |
| Op. Profit | ₹12.09 Cr ▼7.0% | ₹13 Cr ▲18.0% | ₹11.02 Cr ▼3.2% | ₹11.38 Cr ▲20.4% | ₹9.45 Cr ▲20.2% | ₹7.86 Cr ▲14.4% | ₹6.87 Cr ▼21.4% | ₹8.74 Cr |
| OPM | 12.4% ▼6.1% | 13.2% ▲8.4% | 12.2% ▲4.6% | 11.6% ▲6.5% | 10.9% ▲20.5% | 9.1% ▲1.6% | 8.9% ▼28.8% | 12.6% |
| Net Profit | ₹6 Cr ▼28.7% | ₹8.42 Cr ▲51.7% | ₹5.55 Cr ▼31.2% | ₹8.07 Cr ▲129.3% | ₹3.52 Cr ▼2.2% | ₹3.6 Cr ▲86.5% | ₹1.93 Cr ▼40.1% | ₹3.22 Cr |
| EPS (₹) | 1.5 ▼28.9% | 2.11 ▲51.8% | 1.39 ▼31.2% | 2.02 ▲129.5% | 0.88 ▼2.2% | 0.9 ▲87.5% | 0.48 ▼40.7% | 0.81 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
| Revenue | ₹347 Cr ▲20.5% | ₹288 Cr ▼0.7% | ₹290 Cr ▼10.2% | ₹323 Cr ▲51.6% | ₹213 Cr ▲11.5% | ₹191 Cr |
| Expenses | ₹312 Cr ▲19.5% | ₹261 Cr ▼1.9% | ₹266 Cr ▼8.0% | ₹289 Cr ▲52.9% | ₹189 Cr ▲13.2% | ₹167 Cr |
| Op. Profit | ₹36 Cr ▲33.3% | ₹27 Cr ▲12.5% | ₹24 Cr ▼29.4% | ₹34 Cr ▲36.0% | ₹25 Cr ▲4.2% | ₹24 Cr |
| OPM | 10.0% ▲11.1% | 9.0% ▲12.5% | 8.0% ▼20.0% | 10.0% ▼16.7% | 12.0% ▲0.0% | 12.0% |
| Other Income | ₹4 Cr ▲33.3% | ₹3 Cr ▲50.0% | ₹2 Cr ▼50.0% | ₹4 Cr ▲300.0% | ₹1 Cr ▼50.0% | ₹2 Cr |
| Interest | ₹9 Cr ▲12.5% | ₹8 Cr ▲33.3% | ₹6 Cr ▼14.3% | ₹7 Cr ▲75.0% | ₹4 Cr ▲0.0% | ₹4 Cr |
| Depreciation | ₹9 Cr ▼18.2% | ₹11 Cr ▲10.0% | ₹10 Cr ▲11.1% | ₹9 Cr ▲12.5% | ₹8 Cr ▲14.3% | ₹7 Cr |
| PBT | ₹21 Cr ▲90.9% | ₹11 Cr ▲22.2% | ₹9 Cr ▼57.1% | ₹21 Cr ▲40.0% | ₹15 Cr ▲7.1% | ₹14 Cr |
| Tax % | 20.0% ▼25.9% | 27.0% ▲92.9% | 14.0% ▲0.0% | 14.0% ▼17.6% | 17.0% ▼19.0% | 21.0% |
| Net Profit | ₹17 Cr ▲112.5% | ₹8 Cr ▲0.0% | ₹8 Cr ▼55.6% | ₹18 Cr ▲50.0% | ₹12 Cr ▲9.1% | ₹11 Cr |
| EPS (₹) | 4.29 ▲117.8% | 1.97 ▼2.5% | 2.02 ▼58.9% | 4.92 ▲46.0% | 3.37 ▲4.7% | 3.22 |
| Div Payout | 9.0% | 0.0% | 0.0% ▼100.0% | 14.0% ▼30.0% | 20.0% ▲25.0% | 16.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Liabilities | |||||||
| Equity Capital | ₹40 Cr ▲0.0% | ₹40 Cr ▲0.0% | ₹40 Cr ▲0.0% | ₹40 Cr ▲233.3% | ₹12 Cr ▲0.0% | ₹12 Cr ▲0.0% | ₹12 Cr |
| Reserves | ₹122 Cr ▲10.9% | ₹110 Cr ▲23.6% | ₹89 Cr ▲9.9% | ₹81 Cr ▼12.9% | ₹93 Cr ▲38.8% | ₹67 Cr ▲17.5% | ₹57 Cr |
| Borrowings | ₹109 Cr ▼5.2% | ₹115 Cr ▲5.5% | ₹109 Cr ▲43.4% | ₹76 Cr ▼9.5% | ₹84 Cr ▼2.3% | ₹86 Cr ▲65.4% | ₹52 Cr |
| Other Liabilities | ₹44 Cr ▲2.3% | ₹43 Cr ▲19.4% | ₹36 Cr ▲16.1% | ₹31 Cr ▼3.1% | ₹32 Cr ▲0.0% | ₹32 Cr ▲68.4% | ₹19 Cr |
| Total Liabilities | ₹316 Cr ▲2.6% | ₹308 Cr ▲12.8% | ₹273 Cr ▲20.3% | ₹227 Cr ▲2.3% | ₹222 Cr ▲12.7% | ₹197 Cr ▲40.7% | ₹140 Cr |
| Assets | |||||||
| Fixed Assets | ₹102 Cr ▲2.0% | ₹100 Cr ▼7.4% | ₹108 Cr ▲9.1% | ₹99 Cr ▲5.3% | ₹94 Cr ▲8.0% | ₹87 Cr ▲50.0% | ₹58 Cr |
| CWIP | ₹4 Cr ▲100.0% | ₹2 Cr | ₹0 Cr ▼100.0% | ₹13 Cr | ₹0 Cr | ₹0 Cr ▼100.0% | ₹14 Cr |
| Investments | ₹24 Cr ▲4.3% | ₹23 Cr ▲4.5% | ₹22 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other Assets | ₹185 Cr ▲1.1% | ₹183 Cr ▲28.0% | ₹143 Cr ▲23.3% | ₹116 Cr ▼9.4% | ₹128 Cr ▲17.4% | ₹109 Cr ▲60.3% | ₹68 Cr |
| Total Assets | ₹316 Cr ▲2.6% | ₹308 Cr ▲12.8% | ₹273 Cr ▲20.3% | ₹227 Cr ▲2.3% | ₹222 Cr ▲12.7% | ₹197 Cr ▲40.7% | ₹140 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
| Operating CF | ₹1 Cr ▼83.3% | ₹6 Cr ▼84.2% | ₹38 Cr ▲533.3% | ₹6 Cr ▲166.7% | ₹-9 Cr ▼133.3% | ₹27 Cr |
| Investing CF | ₹0 Cr ▲100.0% | ₹-29 Cr ▲3.3% | ₹-30 Cr ▼328.6% | ₹-7 Cr ▲58.8% | ₹-17 Cr ▲0.0% | ₹-17 Cr |
| Financing CF | ₹0 Cr ▼100.0% | ₹23 Cr ▲387.5% | ₹-8 Cr ▼700.0% | ₹-1 Cr ▼103.6% | ₹28 Cr ▲380.0% | ₹-10 Cr |
| Net Cash Flow | ₹1 Cr | ₹0 Cr ▲100.0% | ₹-1 Cr ▲50.0% | ₹-2 Cr ▼200.0% | ₹2 Cr | ₹0 Cr |
| Free Cash Flow | ₹-1 Cr | ₹0 Cr ▼100.0% | ₹10 Cr ▲211.1% | ₹-9 Cr ▲66.7% | ₹-27 Cr ▼370.0% | ₹10 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
| Debtor Days | 49d ▼9.3% | 54d ▲54.3% | 35d ▼12.5% | 40d ▲8.1% | 37d ▲5.7% | 35d |
| Inventory Days | 160d ▼2.4% | 164d ▲27.1% | 129d ▲12.2% | 115d ▼39.5% | 190d ▲72.7% | 110d |
| Days Payable | 37d ▼5.1% | 39d ▲14.7% | 34d ▲13.3% | 30d ▼18.9% | 37d ▲76.2% | 21d |
| Cash Conv. Cycle | 172d ▼3.9% | 179d ▲37.7% | 130d ▲4.0% | 125d ▼34.2% | 190d ▲53.2% | 124d |
| Working Capital Days | 40d ▲42.9% | 28d ▼36.4% | 44d ▲4.8% | 42d ▲20.0% | 35d ▲0.0% | 35d |
| ROCE | 12.0% ▲33.3% | 9.0% ▲12.5% | 8.0% ▼50.0% | 16.0% ▲23.1% | 13.0% | — |
Source: Screener.in · Lower days = better efficiency
About Commercial Syn Bags Limited
Incorporated in 1984, Commercial Syn Bags Ltd manufactuers and exports containers and packaging materials[1]
Capital Goods · Industrial Products